Cell-free circulating epimarks in cancer monitoring

被引:8
|
作者
Duforestel, Manon [1 ,2 ,3 ,4 ]
Briand, Josephine [1 ,2 ,3 ,4 ]
Bougras-Cartron, Gwenola [1 ,2 ,3 ,4 ]
Heymann, Dominique [1 ,2 ]
Frenel, Jean-Sebastien [1 ,2 ,3 ,4 ,6 ]
Vallette, Francois M. [1 ,2 ,3 ,4 ,5 ]
Cartron, Pierre-Francois [1 ,2 ,3 ,4 ,5 ]
机构
[1] Univ Nantes, CRCINA, INSERM, Nantes, France
[2] Inst Cancerol Ouest, LaBCT, Equipe Apoptose & Progress tumorale, St Herblain, France
[3] Niches & Epigenet Tumors Network Canceropole Gran, Nantes, France
[4] EpiSAVMEN Network, Nantes, Region Pays De, France
[5] Univ Nantes, LabEX IGO, Nantes, France
[6] Inst Cancerol Ouest, Dept Med Oncol, Site Rene Gauducheau, St Herblain, France
关键词
biomarkers; cancer; cfc-DNA; cfc-ncRNA; cfc-nucleosomes; epigenetics; FREE DNA; COLORECTAL-CANCER; NUCLEIC-ACIDS; TUMOR DNA; EPIGENETIC MODIFICATIONS; EXTRACELLULAR HISTONES; GENE-EXPRESSION; PLASMA; METHYLATION; CHROMATIN;
D O I
10.2217/epi-2019-0170
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cancer numbers increasing, cases heterogeneity and the drug resistance emergence have pushed scientists to search for innovative solutions for patients and epimutations can be one. Methylated DNA, modified nucleosomes and noncoding RNAs are found in all cells, including tumor cells. They are intracellular actors but also have intercellular communication roles, being released in extracellular environment and in different body fluids. Here, we reviewed current literature on the use of these blood circulating epimarks in cancer monitoring. What stands out is that epimarkers must be considered as 'real time' images of the tumor, and can be isolated without invasive methods. In the future, the real challenge lies in the development of specific, sensitive, fast and clinically applicable detection and analysis methods of epimarkers.
引用
收藏
页码:145 / 155
页数:11
相关论文
共 50 条
  • [1] Cell-free circulating tumor DNA monitoring in pancreatic cancer patients
    Balendran-Braun, S.
    Kieler, M.
    Liebmann-Reindl, S.
    Prager, G. W.
    Streubel, B.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 455 - 455
  • [2] CIRCULATING CELL-FREE TUMOR DNA IN CANCER: POST THERAPY MONITORING
    Francis, Glenn D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 78 - 78
  • [3] Circulating Cell-free Tumor DNA for Individualized Ovarian Cancer Monitoring
    Harris, Faye
    Kovtun, Irina
    Halling, Geoffry
    Kalli, Kimberly
    Johnson, Sarah
    Murphy, Stephen
    Mariani, Andrea
    Vasmatzis, George
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142
  • [4] Circulating cell-free DNA for metastatic cervical cancer detection, genotyping and monitoring
    Kang, Zhigang
    Stevanovic, Sanja
    Hinrichs, Christian
    Cao, Laing
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers
    Chrenkova, Eva
    Studentova, Hana
    Hola, Katerina
    Kahounova, Zuzana
    Hendrychova, Romana
    Soucek, Karel
    Bouchal, Jan
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [6] Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring
    Kang, Zhigang
    Stevanovic, Sanja
    Hinrichs, Christian S.
    Cao, Liang
    CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6856 - 6862
  • [7] Cell-free circulating tumor DNA in cancer
    Zhen Qin
    Vladimir ALjubimov
    Cuiqi Zhou
    Yunguang Tong
    Jimin Liang
    ChineseJournalofCancer, 2016, 35 (05) : 205 - 213
  • [8] Cell-free circulating tumor DNA in cancer
    Qin, Zhen
    Ljubimov, Vladimir A.
    Zhou, Cuiqi
    Tong, Yunguang
    Liang, Jimin
    CHINESE JOURNAL OF CANCER, 2016, 35
  • [9] Cell-free Circulating miRNA Biomarkers in Cancer
    Mo, Meng-Hsuan
    Chen, Liang
    Fu, Yebo
    Wang, Wendy
    Fu, Sidney W.
    JOURNAL OF CANCER, 2012, 3 : 432 - 448
  • [10] Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer
    Hufnagl, C.
    Leisch, M.
    Weiss, L.
    Melchardt, T.
    Moik, M.
    Geisberger, R.
    Asslaber, D.
    Steininger, P.
    Meissnitzer, T.
    Neureiter, D.
    Greil, R.
    Egle, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 307 - 307